相关实验视频

Updated: Jul 10, 2025

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy

Published on: July 3, 2014

乳腺癌患者使用的药物的心脏毒性

Paola Zagami^1,2,3, Dario Trapani^1,3, Eleonora Nicolò^1,3

¹Department of Oncology and Hematology, University of Milano, Milan, Italy.

JCO oncology practice

|November 20, 2023

概括

癌症治疗方法,特别是乳腺癌 (BC),可能会导致幸存者的心脏问题. 早期检测和与心脏瘤学家的团队方法对于管理这些心血管毒性至关重要.

科学领域:

心脏瘤学 - 心脏瘤学
在瘤学瘤学.
心血管医学心血管医学

背景情况:

癌症和心血管疾病是全球死亡和残疾的主要原因.
乳腺癌 (BC) 治疗的进步增加了幸存者数量,但也增加了长期治疗毒性的风险.
心血管毒性是与新批准的BC药物相关的重大不良事件.

研究的目的:

突出与现代乳腺癌疗法相关的心血管不良事件.
强调需要对BC幸存者的心脏毒性保持警.
倡导一种多学科的方法来管理与癌症治疗有关的心血管毒性.

主要方法:

与最近的乳腺癌药物相关的心血管毒性的审查.
讨论癌症药物诱导心血管事件的临床表现.
重点是针对心脏毒性的诊断和治疗策略.

主要成果:

许多最近批准的BC药物 (例如,elacestrant,tucatinib,neratinib,olaparib,免疫检查点抑制剂,trastuzumab deruxtecan,sacituzumab govitecan) 可以诱导心血管不良事件.
这些事件呈现出各种各样的临床表现.
有效的管理需要及时诊断和综合护理.

结论:

心血管毒性是乳腺癌治疗中的一个关键因素.
包括心脏瘤专业知识在内的多学科方法是管理这些不良事件的最佳方式.
警和及时干预是改善心脏毒性BC幸存者的结果的关键.

更多相关视频

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

相关概念视频

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...